GeneNews forms Clinical Advisory Board for its Colorectal Cancer Blood Test

TORONTO, July 25 /PRNewswire-FirstCall/ - GeneNews Limited today announced the appointment of Dr. Bernard Levin to Chair its newly formed Colorectal Cancer Clinical Advisory Board. Dr. Levin has played a key role in the development of clinical practice guidelines for the screening, prevention and diagnosis of colorectal cancer. Dr. Levin was also Chair of the National Colorectal Cancer Roundtable from 1998 to 2005 and is currently Vice-President and Head of the Division of Cancer Prevention and Population Sciences at The University of Texas M. D. Anderson Cancer Center in Houston. The Company intends to appoint additional members to this Board in the near future with regulatory, clinical and commercialization expertise related to early detection of colorectal cancer.

"These advisors will play a vital role in the refinement of our regulatory and commercialization strategies for our lead product, a patient-friendly, blood-based test for detecting and profiling of the patient's risk of having colorectal cancer," said K. Wayne Marshall, MD, PhD, President and Chief Executive Officer of GeneNews. "I am pleased to welcome Dr. Levin as Chair. I am confident that his vast experience developing clinical practice guidelines for colorectal cancer will materially assist the development and clinical introduction of ColonSentry(TM)."

In addition to serving as a vice president at M. D. Anderson, Dr. Levin is a tenured professor of Gastroenterology and maintains a clinical practice at the Gastrointestinal Center at M. D. Anderson mostly confined to people with colorectal neoplasia. He was also the first recipient of the Betty B. Marcus Chair in Cancer Prevention, which was established to promote professional excellence in cancer prevention. Dr. Levin holds an MD from the University of Witwatersrand Medical School in Johannesburg, South Africa. He completed a research fellowship in biochemistry and a clinical fellowship in gastroenterology at the University of Chicago and was a member of its faculty until 1984. He has published more than 250 articles and edited 10 books, the majority of his work focusing on colorectal cancer. Most recently, he was the lead editor of a book entitled American Cancer Society's Complete Guide to Colorectal Cancer published in December 2005. He currently serves on the editorial board of the Journal of the National Institute and Cancer Epidemiology, Biomarkers & Prevention.

About GeneNews

GeneNews is focussed on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. GeneNews' first product in development, ColonSentry(TM), is a blood-based test that can detect colon cancer. For more information on GeneNews, visit www.genenews.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.

CONTACT: Dr. K. Wayne Marshall, President & CEO, (416) 650-0060 x 234,wmarshall@genenews.com; James Smith, (416) 815-0070 x 229,jsmith@equicomgroup.com